Loading...
•
Dec 31, 2023
Supernus Q4 2023 Earnings Report
Supernus reported mixed Q4 2023 results with revenue decrease but growth in key products.
Key Takeaways
Supernus Pharmaceuticals reported a decrease in total revenues for Q4 2023, primarily due to the decline in net product sales of Trokendi XR, which was partially offset by increases in net product sales of Qelbree and GOCOVRI. The company is focused on transitioning to growth products and anticipates several clinical milestones in 2024.
Qelbree net sales increased by 97% compared to Q4 2022.
GOCOVRI net sales increased by 10% compared to Q4 2022.
Total revenues decreased by 2% compared to Q4 2022.
Operating loss was $(1.0) million compared to operating earnings of $34.3 million for the same period in 2022.
Revenue by Segment
Forward Guidance
Supernus expects total revenue between $580 million and $620 million and non-GAAP operating earnings between $80 million and $110 million for the full year 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...